Pancreatic Cancer Research

ResearcherNingbo UniversityActive in the last 2 years

Xiang Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2134-1184; OpenAlex author ID A5033577646. Sources: OpenAlex.

Their work

Papers
8 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
14
Papers, trials and grants by year

2019: 2 papers · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 8

  1. Curcumin suppresses pancreatic cancer progression and glycolysis by modulating the circ_0001535/miR-126-5p/HIPK2 axis. First author DOI 10.1080/1061186x.2026.2646184↗
  2. Deciphering the senescence-based tumoral heterogeneity and characteristics in pancreatic cancer: Results from parallel bulk and single-cell transcriptome data. Co-author DOI 10.1002/iub.70001↗
  3. Hypoxia-Challenged Pancreatic Adenocarcinoma Cell-Derived Exosomal circR3HCC1L Drives Tumor Growth Via Upregulating PKM2 Through Sequestering miR-873-5p. Co-author DOI 10.1007/s12033-024-01091-z↗
  4. Circ_103809 Aggravates the Malignant Phenotype of Pancreatic Cancer Through Modulating miR-197-3p/TSPAN3 Axis. Co-author DOI 10.1007/s12033-023-00874-0↗
  5. Exosome-transmitted hsa_circ_0012634 suppresses pancreatic ductal adenocarcinoma progression through regulating miR-147b/HIPK2 axis. First author DOI 10.1080/15384047.2023.2218514↗
  6. Laparoscopic Pancreatoduodenectomy for Pancreatic Cancer using In-Situ No-Touch Isolation Technique. First author DOI 10.3791/63450↗
  7. Inhibition of LONP1 Suppresses Pancreatic Cancer Progression Via c-Jun N-Terminal Kinase Pathway-Meditated Epithelial-Mesenchymal Transition. Co-author DOI 10.1097/mpa.0000000000001321↗
  8. [MicroRNA-21 correlates TGF-β1 pathway of pancreatic ductal adenocarcinoma]. Co-author DOI 10.11817/j.issn.1672-7347.2019.180708↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Luoluo Wang · 4 shared papers, 2023–2026 · strength 1.03
  2. Xinhua Zhou · 3 shared papers, 2023–2026 · strength 0.81
  3. Xinhua Zhou · 2 shared papers, 2025 · strength 0.47
  4. Yeting Lu · 2 shared papers, 2025 · strength 0.47
  5. Shuo Han · 1 shared paper, 2025 · strength 0.25
  6. Ge Gao · 2 shared papers, 2019 · strength 0.23
  7. Dongjian Ying · 1 shared paper, 2025 · strength 0.22
  8. Hong Li · 1 shared paper, 2024 · strength 0.22
  9. Zhantao Shen · 1 shared paper, 2022 · strength 0.16
  10. Xiaosheng Zhong · 1 shared paper, 2022 · strength 0.16
  11. Can Liu · 1 shared paper, 2019 · strength 0.09
  12. Yong Zhou · 1 shared paper, 2019 · strength 0.09
  13. Hai Wang · 1 shared paper, 2019 · strength 0.09
  14. Gary Guishan Xiao · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.